MedIntelliBase® NewsTips     April 2007

Your monthly newsletter from the
"better way to access market intelligence" people at medintellibase.com

MedIntelliBase® NewsTips...A Better Way...to stay up-to-date


Table of Contents
1) ACC.07 Late-Breaking Updates - American College of Cardiology 56th Annual Meeting
  • COURAGE Trial - Bare Metal Stenting (BMS) vs. Medical Therapy for stable angina
2) New MedIntelliBase Custom Email Alerts
  • MIB Alerts - Stay up-to-date by email on relevant medical industry publications and announcements as they occur
  • Sign up for your Free Personal Tour of MIB Custom Email Alerts
3) Carotid Artery Stenting (CAS)
  • CAS - Read the abstract below of a full article on CAS researched and written by The Next Phase - available upon request
4) Link of the Month
  • Tiny Robots - These tiny robots may change the way some medical procedures are performed
5) Fun Fact of the Month
6) A Better Way...to Access Market Intelligence
7) SidePinch® Clamps (SPCs)
  • SidePinch Clamps - Simple, innovative, incredibly useful - in demand by doctors, nurses, and techs needing easy fluid flow control
8) More Information Available at www.MedIntelliBase.com
Return to Top

1) ACC.07 Late-Breaking Updates - American College of Cardiology 56th Annual Scientific Session

COURAGE Trial - BMS vs. Medical Therapy for stable angina

COURAGE trial results were released March 26, 2007 at the ACC.07 meeting in New Orleans, Louisiana. The study was randomized and involved 2287 patients with objective evidence of myocardial ischemia and significant coronary artery disease (CAD) at 50 U.S. and Canadian centers. Between 1999 and 2004, 1149 patients were assigned to undergo PCI with optimal medical therapy (PCI group) and 1138 to receive optimal medical therapy alone (medical-therapy group). The primary outcome was death from any cause and nonfatal myocardial infarction (MI) during a follow-up period of 2.5 to 7.0 years.

Over the median 4.6 year follow-up, 211 primary events occurred in the PCI group and 202 events were observed in the medical-therapy group. Primary outcome rates were 19.0% in the PCI group and 18.5% in the medical-therapy group (p=0.62). There were no significant differences between the PCI group and the medical-therapy group in the composite of death, myocardial infarction, and stroke (20.0% vs. 19.5%, p=0.62); hospitalization for acute coronary syndrome (12.4% vs. 11.8%, p=0.56); or myocardial infarction (13.2% vs. 12.3%, p=0.33).

Conclusion: PCI did not reduce the risk of death, MI, or other major cardiovascular events when added to optimal medical therapy as an initial treatment for patients with stable CAD.

A detailed snapshot of the COURAGE trial can be viewed at MedIntelliBase.com by clicking on its name link here within. This SMArt Trial™ summary and over 800 other trial summaries are available to subscribers to MedIntelliBase MarketTracks databases. Contact us to access specific clinical trial and registry summaries of interest to you.

Interested in keeping up to date on this issue? Is there another area of interest where you need current, timely clinical research or technology development information? Click here to learn more about our MIB Alerts - A Better Way...to stay up to date.

Return to Top
2) MedIntelliBase Alerts
MIB Alerts
  • MedIntelliBase Custom Email Alerts are highly flexible, customized intelligent search filters powered by "Human Intelligence™" that give you convenient, timely, and tightly focused updates on new developments in your industry segment. MIB Alerts are especially suitable for busy Marketing, Business Development, and General Management executives in medical device and biotechnology companies.
  • Click the banner above for our MIB Alerts overview, or
  • View a sampling of Custom Email Alerts Topics, and
  • See your options for several Alert format styles.
  • Stay up-to-date by email on relevant medical industry publications and announcements as they occur
Return to Top


3) Carotid Artery Stenting (CAS) article abstract written by Vicky Hunsicker Sanko, CEO, The Next Phase

Endovascular disease is a growing problem in the developing world. The carotid artery disease (CAD) subset is a significant patient group. Recently, there have been significant clinical research developments and findings in the race to improve treatment for people with CAD. Carotid artery stenting (CAS) is currently a relatively new and novel option. Vascular intervention that has been proven in the cardio and peripheral vasculature also shows promise as a procedure for CAD. There are many issues unique to the carotid vasculature that significantly separate CAS from traditional cardio and peripheral interventions. It is critical that Clinicians, whether participating in a multi-center trial or for application within general practice, understand these nuances.

Three main clinical issues affect the decision for carotid artery stenting in a candidate patient. First is operator experience. This issue has more direct relation to the procedural outcome than any individual factor or perhaps even all other factors combined. From patient selection, randomization (in trials) and reading of the specific issues unique to each patient with CAD, to the crossing of lesions, use of embolic protection, stent and protection device choice, and the physician’s deployment experience is a key factor.

The second key issue is the current level of regulation for this patient group. Carotid artery stenting is one of the most heavily regulated therapeutic procedures in the world, with influence and control emanating from the FDA and other nations’ regulatory health ministries and bodies. Constituents from tertiary care hospitals and local clinics, differing funding guidelines from public or private providers, and finally the specifications of the device manufacturers all weigh heavily on the clinician. Clearly defining patients at “High Risk” for the established surgery procedure, carotid endarterectomy (CEA), is one of the most controversial current tasks.

The third main issue is the state of the current device pipeline, in terms of products in development, products awaiting approval, and legally marketed products. With the risk of stroke in a carotid procedure ever-present, any and all precautions are justified and necessary. While embolic protection devices are currently under scrutiny for their “cost-effectiveness,” it has been established that given the proper filter placement in conjunction with operator expertise, favorable outcomes can and do occur.

Approximately 700,000 strokes occur in the United States every year. Of this total, 500,000 are first-time events for new patients while 200,000 are recurrent in patients that suffered prior stroke events. It is estimated that 25% of all strokes are caused by carotid artery disease (CAD). In the US alone, the market for stroke prevention caused by CAD and suitable for carotid vascular therapy is about 175,000 procedures per year. This can be further broken down by treatment type: surgery, vascular intervention or some form of drug treatment.

Demographically, there are a number of factors that determine who suffers from carotid artery disease and who does not. With these factors patients fall into groups that are more appropriately suited for certain procedures over others. In the U.S., CAS for example is currently prescribed for “high risk” patients only. The latest offshoot of the Framingham study is an example of what work is being undertaken to further understand which demographic factors can predict outcomes. Other trials have studied the issue based on race, sex, and certain health factors.

Interested in keeping up to date on this issue? The full, frequently updated Carotid Artery Stenting article is available upon request when you sign-up for our custom MIB Alerts tour. Click here to request your copy of the article - please be sure to indicate your interest in the full CAS article in the comments box.

Is there another area of interest where you need current, timely clinical research or technology development information? Click here to learn more about our
MIB Alerts - A Better Way...to stay up to date.

Return to Top


4) Link of the Month
  • Tiny Robots- Researches from Ritsumeikan University and the Shiga University of Medical Science (Japan) have developed a mini-robot prototype that can be manipulated within a body by an external magnetic field. The robot has the potential to perform medical treatments as well as capture images. [www.pinktentacle.com]
Return to Top


5) Fun Fact of the Month
  • Need a quick mental boost? - It is said that an ounce of pickled ginger can temporarily raise your IQ by as many as 10 points. Browse the link to find a recipe or visit your favorite sushi bar when you need a moment of brilliance. [www.factropolis.com]
Return to Top


6) MedIntelliBase Custom Email Alerts now give you A Better Way

New feature just added - full-featured search capabilities in your subscribed libraries. Search any or all of these databases:

  • Abstracts Library Alerts Library Full Text Article Library
  • MarketTracks...detail backgrounders on breaking clinical trial and emerging technologies summaries.
A Better Way
Does this "quest for Market Intelligence" sound familiar?
  1. Search for market, clinical, or technology "intelligence"
  2. Agonize over the high prices
  3. “Bite the bullet” and purchase an email alert service
  4. Sort through reams of semi-useful results with every alert
  5. Marvel at the lack of precise targeting and time you spend using your human intelligence to screen-out bad results
  6. Give up and spend hours trying to find the latest developments on Medline or Google
  7. Search for hours to find that one exact abstract or press release from 3 or 4 months ago that supports your point
  8. Get frustrated at the inability to find what you need
  9. Write your report or your business plan that you know should be better, more in depth and more precise...if only you had better information
  10. Vow that next time, you’ll find a better way
MedIntelliBase Alerts now with MarketTracks databases give you just that...A Better Way:

     

MIB Alerts
MedIntelliBase Custom Email Alerts are highly flexible, customized intelligent search filters powered by "Human Intelligence™" that give you convenient, timely, and tightly focused updates on new developments in your industry segment. MIB Alerts are especially suitable for busy Marketing, Business Development, and General Management executives in medical device and biotechnology companies.

Convenient and Timely

    • Respond to new developments in real time, not weeks or months later
    • Keep you up-to-date on relevant industry events and announcements as they occur
    • Pushed to you via email, no need to login for news

Easy to use

    • MIB Alerts do the work for you. You become the "industry expert" in your organization
    • Easy-to-read and navigate Alerts and archives
    • Fully-searchable online libraries of abstracts, articles, Alerts, clinical trial and technology summaries - you choose and customize to your exact requirements
    • Easy-to-search libraries of abstracts, Alerts or articles that return  documents quickly, within your first query
    • Accessible from anywhere, from Outlook or any web browser

Customized and Tightly Focused

    • Save you time and make you more effective
    • You receive only those specific developments that matter to you
    • You don't receive useless filler and irrelevant search hits - MIB's "Human Intelligence" removes the fluff

A few examples of thousands of possibilities for Alert topics:

Cardiac, Cardiovascular and Vascular

  • Peripheral Arterial Occlusion (PAO)- Thrombolysis
  • Cardiac Structural Defects
  • Lower Limb PAD & Atherectomy
  • PV Angiography - Infusion Catheters
  • CV/PV Angiography - Power Injectors
  • Deep Vein Thrombosis (DVT) - Thrombolysis

Neurology

  • Neurostimulation - Hearing Loss
  • Neurostimulation - Alzheimer's disease
  • Neurostimulation - Parkinson's disease
  • Drugs and Advanced Therapies - Parkinson's disease & Essential Tremor
  • Neurostimulation - Epilepsy
  • Neurostimulation - Pain Management

Orthopedic

  • Spinal Motion Preservation
  • Hip Resurfacing
  • Knee Resurfacing

Emergency Medicine

  • Resuscitation

View a sampling of Custom Email Alerts

Customize your Alerts with the type of information you specify:

  • Clinical article abstracts
  • Trials and registries results
  • Preclinical article abstracts
  • Industry announcements
  • Press releases
  • Conference notices & proceedings
  • Technology developments
  • Patents issued & challenged
  • Lawsuits & other legal issues
  • FDA & voluntary product recalls
  • And more

Other custom consulting options:

  • Tracking of established and emerging technologies, landmark and breaking trials and competing companies
  • Strategic analysis and recommendations
  • Market potential assessments
Click the banner below to view sample MIB Custom Email Alert formats - a "FullView" Alert, or one of the "QuickView" formats --> Lean Alert or UltraLean Alert:

MIB Alerts


You get much greater value from customizable MIB Alerts than from standard market reports and search engines. You choose the exact depth and breadth of intelligence required, realizing the greatest value for your market intelligence money.

Interested? Want to know more? Want a trial?

Contact us for:
  • More information
  • Real-Time MedIntelliBase Custom Email Alerts  Tour
Return to Top


7) SidePinch Clamps

SidePinch Clamps
(SPCs) are in demand for easy "on-off" use...
  • One hand operation - place, lock, unlock
  • Easy on, easy off
  • No need to break any connection
  • Available in a variety of sizes
  • Custom configurations available
SPCs are designed for on-demand fluid flow control in a variety of clinical, medical, emergency and laboratory settings.

Doctors, nurses, lab technicians and other medical practitioners require smarter closing, clamping and contamination-prevention devices which are easy-to-use and a great value.
SidePinch Clamps meet their needs.

Find out how by visiting www.SidePinchClamp.com
SPC1
SPC2

Return to Top

8) More Information Available at www.MedIntelliBase.com

You can find more in-depth information about MedIntelliBase Custom Email Alerts - visit the website at www.MedIntelliBase.com or request more information on the site.

MedIntelliBase MarketTracks and Alerts will help you find the critical intelligence you need to make informed product development and business investment decisions.

Contact MedIntelliBase directly...

Return to Top


FYI:
  1. MedIntelliBase NewsTips is free and you are welcome to continue receiving it as long as you wish. If at any time you wish to cancel just click the Safe Unsubscribe link below.
  2. We will not share your name and e-mail address with anyone.
  3. Feel free to share or reproduce the information in this MedIntelliBase NewsTips e-newsletter (in whole or part) as long as proper mention and copyright notice is given to MedIntelliBase and The Next Phase Publishing**.
  4. If you are not the original recipient of this newsletter and would like to receive future issues, just click the Forward link below or drop us a line.

Editor: Vicky Hunsicker Sanko
The Next Phase Publishing**
Phone - 425/869-8724

Market Research Analyst: Jordan Zornes
The Next Phase Publishing**
Phone - 425/894-4147

www.MedIntelliBase.com
Toll Free - 800/390-2756
Fax - 866/381-6119

** A division of Next Phase® Consultancy, Inc.

© The Next Phase® Consultancy, Inc. 2007. All rights reserved.

Return to Top